Tofacitinib For Treatment Of Chronic Pouchitis

• Status: Recruiting
• Trial end date: 2022-02-01
• Target enrollment: 0
• Participant gender: All

Summary

A phase 2 pilot study to evaluate the effectiveness of tofacitinib in subjects with chronic pouchitis

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Cedars-Sinai Medical Center
• Treatments: Tofacitinib

Criteria

Inclusion Criteria:

1. Male or female subjects ages 18 to 80

2. Subjects with a history of proctocolectomy with ileal pouch anal anastomosis (IPAA) for UC at least 6 months prior to screening.

3. Subjects with pouchitis that is chronic, defined by a mPDAI score ≥5 assessed as the average from 3 days immediately prior to the baseline study visit and a minimum endoscopic sub-score of 2 (outside the staple or suture line) with either (a) ≥ 3 recurrent episodes within 1 year prior to the screening treated with ≥2 weeks of antibiotic or other prescription therapy, (b) requiring maintenance antibiotic therapy taken continuously for ≥4 weeks immediately prior to the baseline study visit

4. Women of childbearing potential must have documentation of a negative pregnancy test at screening and must agree to use two highly effective methods of birth control during the study and for at least 1 month after completion of study drug dosing.

Exclusion Criteria:

1. Subjects with IPAA surgery done for Crohn's disease (CD) or familial adenomatous polyposis (FAP) indications.

2. Subjects with primary CD of pouch, isolated or predominant cuffitis or mechanical complications of the ileal pouch.

3. Subjects with prior exposure to tofacitinib.

4. Subjects with a diverting stoma.

5. Subjects with a prior history or risk factors for venous thromboembolism.

6. Subjects with active bacterial, parasitic, fungal, mycobacterial, or viral infection.

7. Subjects with a history of latent or active tuberculosis.

8. Subjects positive for hepatitis B virus (HBV) surface antigen, hepatitis B virus core antibody with a negative hepatitis B surface antibody or with detectable serum hepatitis B DNA.

9. Female subjects who are pregnant or lactating.

10. Female subjects of childbearing potential who are sexually active and do not agree to using two highly effective methods of contraception during the study period.

11. Subjects with clinically significant laboratory abnormalities at study screening.

• Other eligibility criteria apply